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Montserrat Fragaa, Nicolas Fournierb, Ekaterina Safroneevad, Valérie Pittetb, Sébastien Godata, Alex Straumanne,
Andreas Nydeggerc, Stephan R. Vavrickaf,g, Darius Moradpoura and Alain M. Schoepfera; on behalf of the Swiss
IBD Cohort Study Group
Background and aim Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal
manifestation of inﬂammatory bowel disease (IBD). We aimed to assess the prevalence of PSC in the Swiss Inﬂammatory Bowel
Disease Cohort Study, to identify associated risk factors, and to describe the long-term evolution.
Patients and methods Data of patients enrolled into the Swiss Inﬂammatory Bowel Disease Cohort Study were analyzed.
Logistic regression modeling was performed to identify risk factors for PSC.
Results Among 2744 patients [1188 ulcerative colitis (UC); 1556 Crohn’s disease (CD)], 57 had PSC (48 UC-PSC, nine CD-
PSC). The prevalence of PSC was higher in UC compared with CD (4.04 vs. 0.58%, P< 0.001). We identiﬁed the following
signiﬁcant independent risk factors for PSC in patients with UC: male sex [odds ratio (OR) 2.771, P=0.022], pancolitis (OR 2.855,
P=0.011), nonsmoker at diagnosis (OR 9.253, P= 0.030), and a history of appendicectomy (OR 4.114, P=0.019). During a
median follow-up time of 74.8 months, four (7.0%) of PSC patients developed cholangiocarcinoma, six (10.5%) underwent liver
transplantation, and ﬁve (8.8%) died. Survival of IBD-PSC patients was signiﬁcantly worse compared with IBD patients without
PSC (P=0.001). UC-PSC patients developed signiﬁcantly more frequently colorectal cancer compared with UC patients without
PSC (2/48 vs. 9/1440, P=0.017).
Conclusion Approximately 4% of UC patients and 0.6% of CD patients had PSC. Male sex, pancolitis, nonsmoker status, and a
history of appendicectomy were signiﬁcantly associated with PSC. PSC is associated with considerable morbidity and mortality in
the long term. Eur J Gastroenterol Hepatol 29:91–97
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC), sum-
marized under the term inﬂammatory bowel diseases
(IBD), are chronic inﬂammatory disorders of the gastro-
intestinal tract that develop from a dysregulated mucosal
immune response to commensal gut ﬂora in genetically
susceptible individuals [1,2].
Various extraintestinal manifestations can be associated
with IBD [3]. Primary sclerosing cholangitis (PSC) repre-
sents the main hepatobiliary extraintestinal manifestations
related to IBD. PSC-associated IBD can be found in
60–80% of affected patients [4]. Conversely, PSC may be
observed with a lifetime prevalence of about 5% of
patients with UC and less frequently in patients with CD
[5]. PSC is a chronic and progressive disorder character-
ized by inﬂammation, ﬁbrosis, and the stricturing pro-
cesses in the intrahepatic and extrahepatic biliary tree,
leading to end-stage liver disease and associated compli-
cations such as cholangiocarcinoma [6,7]. Median survival
without liver transplantation after PSC diagnosis is 10 to
12 years [8–10]. The exact pathogenesis of PSC is
unknown, but environmental as well as genetic factors
likely contribute [11,12].
Patients with IBD and concomitant PSC may be char-
acterized by a distinct IBD phenotype that differs from IBD
patients without PSC. Pancolitis has been reported to be
more prevalent in IBD patients with concomitant PSC
compared with IBD patients without PSC [13,14].
Data on the prevalence of PSC, associated risk factors,
and natural history from large cohort studies are still
limited. Thus, we aimed to answer the following questions
using data from the Swiss Inﬂammatory Bowel Disease
Cohort Study (SIBDCS). First, what is the PSC prevalence
in all IBD patients and what is the PSC prevalence strati-
ﬁed according to UC and CD? Second, which independent
risk factors are associated with PSC in IBD patients?
Third, which clinical criteria characterize PSC-IBD patients
compared with IBD patients without concomitant PSC?
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Finally, what is the long-term morbidity and mortality of
PSC in patients with IBD?
Patients and methods
Patients
Since 2006, IBD patients from all regions of Switzerland
have been included in the nationwide SIBDCS that is
supported by the Swiss National Science Foundation and
approved by the local ethical committees [15]. Data
acquisition focuses on clinical, socioeconomic, and psy-
chosocial data. Written informed consent is mandatory for
inclusion into this cohort as well as permanent residence
status in Switzerland or Swiss health insurance. A thor-
ough clinical and laboratory assessment is performed
at the time of enrollment. Patients attend follow-up visits
at least once a year. The enrollment and follow-up
questionnaires capture clinical, socioeconomic, and psy-
chosocial data. Questionnaires assessing the clinical char-
acteristics of IBD patients are completed by the treating
physicians, whereas questionnaires that assess, among
others, quality of life, social impairment, and symptoms,
are completed by IBD patients themselves. Data obtained
from patients included in the SIBDCS between July 2006
and May 2014 were analyzed in this study. Patients
included in the SIBDCS were recruited in the following
healthcare settings: 61% at university hospitals, 13% in
large nonuniversity hospitals, 6% in cantonal hospitals,
and 20% in private practices across Switzerland.
Methods
Data obtained from questionnaires completed by patients
and physicians were collected and validated in the data
center of the SIBDCS. Rigorous rules were followed to
ensure data quality. The diagnosis of PSC was made on the
basis of either characteristic alterations of the biliary tree
on magnetic resonance cholangiography or endoscopic
retrograde cholangiography [16]. The following disorders
had to be excluded before PSC was diagnosed: recurrent or
chronic bacterial cholangitis, infectious or ischemic cho-
langiopathy, choledocholithiasis, diffuse intrahepatic
metastases, recurrent pancreatitis, IgG4-associated cho-
langitis, biliary tree alterations after intra-arterial che-
motherapy, portal hypertensive biliopathy, and surgical
biliary trauma. Liver enzyme abnormalities were not
assessed systematically. As information on liver trans-
plantation and PSC-related mortality was not system-
atically recorded in the questionnaires, the authors
contacted the treating physicians of all IBD patients with
concomitant PSC to request the following additional
information: time of PSC diagnosis, diagnostic modalities,
development of cholangiocarcinoma, necessity to undergo
liver transplantation related to PSC, and PSC-associated
mortality.
Disease location was grouped according to the
Montreal classiﬁcation [17]. For CD, L1 denotes disease in
the terminal ileum, L2 denotes disease in the colon, L3
denotes ileocolonic disease, and L4 denotes isolated dis-
ease in the upper gastrointestinal tract. For UC, E1 denotes
ulcerative proctitis, E2 denotes left-sided colitis, and E3
denotes extensive colitis.
Statistical analysis
Clinical data were retrieved from the SIBDCS Data Center
(Institute of Social and Preventive Medicine, University of
Lausanne). All statistical examinations were performed
using a statistical package program (STATA, version 12.1;
StataCorp., College Station, Texas, USA). Data distribu-
tion was analyzed using normal-QQ-plots. Results of the
analysis of the quantitative data are presented as either
mean± SD and range (for Gaussian data) or median and
interquartile range (IQR) (for non-Gaussian data).
Categorical data were summarized as the percentage of the
group total. Differences in distributions of quantitative data
were assessed using Student’s t-test (for Gaussian data) and
the Wilcoxon rank-sum test (for non-Gaussian data).
Differences between the frequencies for categorical data
were assessed using the χ2-test or the Fisher’s exact test in
case of a small sample size.
To identify factors associated with PSC in IBD, multi-
variate logistic modeling was performed. First, age at the
time of diagnosis, sex, disease location at the time of
diagnosis, smoking status at the time of diagnosis, and
history of appendicectomy were entered as dichotomous
variables, and IBD disease duration was entered as a
continuous variable into the univariate logistic regression
model. Univariate variables with a P-value less than 0.15
were entered into the multivariate logistic model. The
results are presented as odds ratio, 95% conﬁdence inter-
val, and corresponding P-values. Survival curves for PSC-
related mortality were calculated according to the
Kaplan–Meier method. A P-value of less than 0.05 was
considered to be statistically signiﬁcant.
Results
Prevalence of PSC in the SIBDCS and clinical
characteristics of the PSC-IBD patients
Among 2744 IBD patients [of whom 1556 (56.7%) had
CD and 1188 (43.3%) had UC], 57 patients with PSC
were identiﬁed. Of these, 48 (84.2%) had underlying UC
(UC-PSC) and nine (15.8%) had CD (CD-PSC). The
cumulative PSC prevalence was 4.04% in UC patients and
0.58% in CD (P<0.001). PSC was signiﬁcantly more
prevalent in men compared with women (risk ratio 2.54,
P= 0.001).
The clinical characteristics of UC and CD patients with
concomitant PSC are shown in Table 1. Compared with
CD-PSC patients, UC-PSC patients were characterized by
the following ﬁndings: they underwent signiﬁcantly less
frequently intestinal (small bowel) surgery (10.4 vs.
44.4%, P=0.027) and perianal ﬁstula/abscess surgery (4.2
vs. 33.3%, P=0.024), but they underwent colectomy
signiﬁcantly more frequently (39.6 vs. 0%, P= 0.022).
Furthermore, UC-PSC patients were signiﬁcantly less fre-
quently smoking at IBD diagnosis compared with CD-PSC
patients (4.2 vs. 44.4%, P< 0.001). 5-Aminosalicylic acid
was more frequently used (ever) in UC-PSC patients (85.4
vs. 44.4%, P=0.015) compared with CD-PSC patients,
whereas immunomodulators were less frequently applied
(ever) (54.2 vs. 100%, P= 0.009).
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Comparison of UC-PSC patients to UC patients without
PSC
The clinical characteristics and outcomes of the UC-PSC
patients (n=48) compared with the UC patients without
PSC (n=1140) are shown in Table 2. The length of the
follow-up period was comparable between the groups
(69.6 months for UC patients vs. 73.5 months for UC-PSC
patients, P= 0.731).
Compared with UC patients without PSC, UC-PSC
patients were more frequently men (77.1 vs. 53%,
P= 0.001), they were younger at UC diagnosis (median 24
vs. 31 years, P=0.001), they more often had pancolitis
(55.3 vs. 37.8%, P= 0.017), and they more often under-
went colectomy (39.6 vs. 8.3%, P<0.001).
Among the 48 UC-PSC patients, we identiﬁed four
(8.3%) patients with cholangiocarcinoma. In one patient,
the cholangiocarcinoma was found only in the explanted
liver after transplantation. Of the 48 UC-PSC patients, six
(12.5%) underwent liver transplantation because of
recurrent episodes of cholangitis (12.5%). During follow-
up, ﬁve (10.4%) UC-PSC patients died. The cause of death
was cholangiocarcinoma in four patients, whereas one
patient died because of advanced liver dysfunction while
awaiting liver transplantation. In UC patients without
concomitant PSC, the occurrences of cholangiocarcinoma
and liver transplantation were not assessed systematically
by the cohort questionnaires.
Comparison of CD-PSC patients with CD patients
without PSC
The clinical characteristics and outcomes of the CD-PSC
patients compared with the CD patients without PSC are
shown in Table 3. Out of 1556 CD patients, a total of nine
patients (0.6%) had concomitant PSC (CD-PSC). On
comparing CD-PSC patients and CD patients without
PSC, we observed no statistical difference in the different
items. Any comparison between these two groups is lim-
ited, given the small number of CD-PSC patients.
Risk factor analysis for PSC in UC patients
We performed ﬁrst univariate and then multivariate
logistic regression modeling to identify independent risk
factors for the occurrence of PSC in UC patients. The
results are shown in Table 4. Male sex, nonsmoker status,
pancolitis at diagnosis, as well as a history of appendi-
cectomy were found to be associated independently with
PSC in UC patients.
Table 1. Clinical and demographic characteristics of patients with IBD
with concomitant PSC
Crohn’s disease Ulcerative colitis P-value
Number of patients 9 48 –
Male [n (%)] 4 (44.4) 37 (79.3) 0.099
Age at IBD onset (years) 0.930
Median 23 24
IQR 21–28 18–35
Range 17–48 10–64
IBD duration (years) 0.784
Median 15 13
IQR 8–22 7–21
Range 4–37 2–44
PSC duration (years) 0.594
Median 6 7
IQR 4.5–8 5–13
Range 4–9 3–22
BMI (kg/m2) 0.938
Median 22 22
IQR 21–23 21–24
Range 18–31 17–48
Intestinal surgery [n (%)] 0.027
No 5 (55.6) 43 (89.6)
Yes 4 (44.4) 5 (10.4)
Fistula/abscess surgery [n (%)] 0.024
No 6 (66.7) 46 (95.8)
Yes 3 (33.3) 2 (4.2)
Colectomy 0.022
No 9 (100.0) 29 (60.4)
Yes 0 (0.0) 19 (39.6)
Family history of IBD [n (%)] 0.790
None 9 (100.0) 39 (81.3)
Yes 0 (0.0) 4 (8.3)
Unknown 0 (0.0) 5 (10.4)
Smoking status (at diagnosis) [n (%)]
Nonsmoker 5 (55.6) 42 (87.5) 0.021
Smoker 4 (44.4) 2 (4.2) <0.001
Unknown 0 (0.0) 4 (8.3) 0.369
Colorectal cancer [n (%)] 1.000
No 9 (100.0) 46 (95.8)
Yes 0 (0.0) 2 (4.2)
EIM other than PSC [n (%)] 0.146
No 3 (33.3) 30 (62.5)
Yes 6 (66.7) 18 (37.5)
History of therapy (ever) [n (%)]
5-ASA 4 (44.4) 41 (85.4) 0.015
Steroids 7 (77.8) 38 (79.2) 1.000
Immunomodulators 9 (100.0) 26 (54.2) 0.009
Anti-TNF agents 5 (55.6) 18 (37.5) 0.461
Calcineurin inhibitors 1 (11.1) 10 (20.8) 0.673
5-ASA, 5-aminosalicylic acid; EIM, extraintestinal manifestations; IBD, inﬂammatory
bowel disease; IQR, interquartile range; PSC, primary sclerosing cholangitis; TNF,
tumor necrosis factor.
Table 2. Demographic and clinical characteristics of patients with UC
with and without PSC
Demographic and clinical
features
UC-PSC
(n=48)
UC alone
(n=1140) P-value
Male [n (%)] 37 (77.1) 604 (53) 0.001
Age at diagnosis of UC (years)
Median 24 31 0.001
IQR 18–35 23–40
Range 10–64 3–82
Disease location at diagnosis
[n (%)]
<0.001*
E1 (proctitis) 1 (2.1) 231 (20.3)
E2 (left-sided colitis) 10 (20.8) 378 (33.2)
E3 (extensive/pancolitis) 26 (54.2) 432 (37.9)
Unknown/unclear location
[n (%)]
11 (22.9) 99 (8.7)
Follow-up (months) 0.731
Median 76.5 69.6
IQR 44.6–97.6 43.9–93.3
Range 19.6–107.0 2.0–109.3
Disease duration (years) 0.005
Median 13 9
IQR 7–20.5 5–16
Range 2–44 0–58
Colectomy [n (%)] 19 (39.6) 95 (8.3) <0.001
Colorectal cancer [n (%)] 2 (4.2) 9 (0.8) 0.017
Cholangiocarcinoma [n (%)] 4 (8.3) NA NA
Liver transplantation [n (%)] 6 (12.5) NA NA
Mortality [n (%)] 5 (10.4) 20 (1.8) 0.003
Disease location is recorded according to the Montreal classiﬁcation [17].
IQR, interquartile range; NA, not available; PSC, primary sclerosing cholangitis;
UC, ulcerative colitis; UC-PSC, ulcerative colitis associated with primary sclerosing
cholangitis.
P-values for distinct locations: proctitis, P=0.002; left-sided colitis, P=0.044;
pancolitis, P=0.017; unknown disease location, P<0.001.
*P-value for all disease locations together.
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No regression modeling for the identiﬁcation of risk
factors for concomitant PSC was performed in CD
patients, given the limited patient number.
Long-term evolution of IBD-PSC patients
The long-term evolution of IBD-PSC patients was char-
acterized by considerable morbidity and mortality. During
a median follow-up time of 74.8 months (6.3 years),
6/57 (10.5%) of IBD-PSC patients underwent liver
transplantation because of progressive liver failure and/or
recurrent episodes of bacterial cholangitis. All patients
who underwent transplantation had underlying UC. In one
of the transplanted patients, a cholangiocarcinoma was
identiﬁed in the explanted liver. The median time interval
from PSC diagnosis to diagnosis of cholangiocarcinoma
(n=4) was 6 years (IQR 3.5–9, range 3–10 years) and
6.5 years (IQR 3–11, range 3–19 years) from PSC diag-
nosis to liver transplantation (n= 6). During the follow-up
period, 5/57 (8.8%) of IBD-PSC patients died; all of them
had underlying UC. Survival of IBD-PSC patients was
signiﬁcantly worse compared with IBD patients without
concomitant PSC (Fig. 1, P=0.001). Mortality in UC-PSC
patients during the follow-up period was 10.4% (5/48) for
PSC-UC patients compared with 1.8% (20/1440) for UC
patients without concomitant PSC (P= 0.003, Table 2).
No difference in mortality was identiﬁed on comparing
CD-PSC patients (n= 9) with CD patients without con-
comitant PSC (n=1547, P=0.612, Table 3).
All IBD patients with cholangiocarcinoma had UC.
A total of 4/48 (8.3%) of UC-PSC patients developed
Table 3. Demographic and clinical characteristics of patients with CD
with or without PSC
Demographic and clinical features CD-PSC (n=9)
CD alone
(n=1547) P-value
Male [n (%)] 4 (44.4) 733 (47.4) 1.000
Age at diagnosis of CD (years) 0.500
Median 26 23
IQR 19–36 21–28
Range 4–81 17–48
Disease location at diagnosis [n (%)]
L1 (ileal) 2 (22.2) 353 (22.8)
L2 (colonic) 4 (44.4) 317 (20.5) 0.25
L3 (ileocolonic) 3 (33.3) 700 (45.3)
L4 (upper gastrointestinal tract)
only
0 13 (0.8)
Unknown/unclear location 0 164 (10.6)
Follow-up duration (in the SIBD
Cohort Study) (months)
0.103
Median 101.6 72.4
IQR 49.6–104.6 45.2–96.5
Range 24.7–107.0 0.6–113.3
Disease duration (years) 0.397
Median 15 11
IQR 8–22 5–20
Range 4–37 0–55
Small intestine/colonic surgery
[n (%)]
1 (11.1) 476 (38.2) 0.202
Colorectal cancer [n (%)] 0 (0.0) 4 (0.3) 0.879
Cholangiocarcinoma [n (%)] 0 NA NA
Hepatic failure [n (%)] 0 NA NA
Liver transplantation [n (%)] 0 NA NA
Mortality [n (%)] 0 43 (2.8) 0.612
CD, Crohn’s disease; CD-PSC, Crohn’s disease associated with primary scler-
osing cholangitis; IQR, interquartile range; NA, not available; SIBD, Swiss
Inﬂammatory Bowel Disease.
Table 4. Univariate and multivariate logistic regression models to evaluate risk factors for PSC in patients with UC
PSC in patients with UC
Univariate model Multivariate model
Outcome OR 95% CI P-value OR 95% CI P-value
Age at the time of diagnosis (years)
<40 1 (ref) – – 1 (ref) – –
≥40 0.435 0.182–1.033 0.059 0.568 0.210–1.537 0.266
Sex
Female 1 (ref) – – 1 (ref) – –
Male 2.994 1.511–5.917 <0.001 2.771 1.154–6.649 0.022
Pancolitis at diagnosis
No 1 (ref) – – 1 (ref) – –
Yes 3.676 1.757–7.692 0.001 2.855 1.276–6.390 0.011
Smoking status at the time of diagnosis
Smoker 1 (ref) – – 1 (ref) – –
Nonsmoker 5.682 1.364–23.810 0.017 9.253 1.235–69.341 0.030
Disease duration from the time of diagnosis (years) 1.040 1.012–1.068 0.004 1.033 0.994–1.074 0.100
Appendicectomy
No 1 (ref) – – 1 (ref) – –
Yes 3.361 1.135–9.954 0.029 4.114 1.268–13.354 0.019
CI, conﬁdence interval; OR, odds ratio; PSC, primary sclerosing cholangitis; UC, ulcerative colitis.
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Fig. 1. Cumulative survival of patients with IBD with and without PSC. IBD,
inﬂammatory bowel disease; PSC, primary sclerosing cholangitis.
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cholangiocarcinoma during the follow-up interval. As
such, the annual incidence rate of cholangiocarcinoma in
UC-PSC patients was 1.3%.
With a comparable median length of follow-up (76.5
vs. 69.6 months), UC-PSC patients developed signiﬁcantly
more frequently a colorectal cancer compared with UC
patients without concomitant PSC (2/48 vs. 9/1440,
P= 0.017, Table 2). However, it has to be taken into
account that the median disease duration was longer in
UC-PSC patients compared with UC patients without
concomitant PSC (13 vs. 9 years, P= 0.005). A longer
disease duration increases the risk of being diagnosed with
colorectal cancer.
Discussion
We present data from the large and well-characterized
SIBDCS on the prevalence of PSC, associated risk factors,
and the long-term outcome. Our study reports several
observations that are clinically relevant: ﬁrst, PSC is more
prevalent in UC than in CD patients. Second, male sex and
pancolitis at diagnosis are risk factors for PSC. Third, the
mortality of IBD patients with concomitant PSC is sig-
niﬁcantly higher compared with IBD patients without PSC.
Over a median disease duration of 13 years for UC and
15 years for CD, we observed a PSC prevalence of 4.04%
in UC patients and of 0.58% in CD patients. Our pre-
valence data are in accordance with the ﬁndings from
Olsson et al. [18], who conducted a survey in 1500 UC
patients in Sweden. Of these, 72 patients (4.8%) were
identiﬁed to have elevated serum alkaline phosphatase. On
the basis of the ﬁndings of endoscopic retrograde cho-
langiopancreatography, which was performed in 65
patients, PSC was diagnosed in 55/1500 UC patients
(3.7%). Again, similar to our ﬁndings, the authors found
that PSC was more prevalent in men and more prevalent in
UC patients with pancolitis compared with patients with
distal colitis [18]. Furthermore, our ﬁndings are in line
with the data of Broomé et al. [19], who evaluated 1274
UC patients with a follow-up period of 3 years, during
which 29 patients (2.3%) developed PSC. During the
follow-up period, 12 PSC patients died, four because of
cholangiocarcinoma and eight because of hepatic failure,
whereas one patient underwent liver transplantation [19].
In accordance with our ﬁndings, the authors observed an
increased mortality in UC patients with concomitant PSC
compared with patients with UC without PSC. Given the
longer follow-up period, it is to be expected that the PSC
prevalence in the SIBDCS is slightly higher compared with
the data from Broomé and colleagues.
In our cohort, PSC prevalence in CD patients (0.58%)
was clearly lower compared with UC patients (4.04%).
Despite a comparable follow-up time of 15 years, the PSC
prevalence in CD patients is lower than that reported by
Rasmussen et al. [20], who diagnosed PSC, on the basis of
liver enzyme abnormalities and compatible ﬁndings in
endoscopic retrograde cholangiopancreatography, in
9/262 (3.4%) of CD patients. It is noteworthy that all PSC-
affected CD patients in that study had colonic involve-
ment [20].
We carried out an extensive analysis on potential
associated factors for PSC development in UC patients by
means of logistic regression modeling. We identiﬁed male
sex, pancolitis at UC diagnosis, nonsmoker status at
diagnosis, as well as a history of appendicectomy as factors
signiﬁcantly associated with a diagnosis of PSC. Our data
conﬁrm the ﬁndings of Joo et al. [21], who previously
reported that UC patients with PSC had more frequently
extensive disease and pancolitis, when compared with UC
patients without concomitant PSC. In addition, we were
also able to reproduce the already published evidence that
male sex is a risk factor for PSC development among UC
patients [22]. We found cigarette smoking at UC diagnosis
to be a signiﬁcant independent protective factor for PSC
development (odds ratio 0.12, P=0.040). The protective
effect of cigarette smoking on PSC development was
already shown two decades ago [23,24]. Controversial
evidence is found in the literature on the impact of
appendicectomy on the risk of PSC development. In our
cohort, a history of appendicectomy was an independent
signiﬁcant risk factor for PSC development. This ﬁnding is
not in line with data from Florin et al. [25] as well as
Mitchell et al. [26], who did not ﬁnd that appendectomy
increased the risk for PSC. As a word of caution, we need
to mention that the SIBDCS questionnaires did not assess
the exact year of appendicectomy. As such, the temporal
relationship between appendicectomy and PSC diagnosis
remains unclear.
The long-term outcome of IBD patients with PSC in the
SIBDCS was characterized by considerable morbidity and
mortality. Survival of IBD-PSC patients was signiﬁcantly
worse compared with IBD patients (P= 0.001). During a
follow-up period of 6.3 years, 8.3% (4/48) of UC-PSC
patients developed cholangiocarcinoma, which results in
an annual incidence rate of 1.3%. As such, our data are in
accordance with the results from Bergquist et al. [27], who
determined in a large cohort study comprising 604
Swedish PSC patients an annual incidence rate of cho-
langiocarcinoma of 1.5%. The Swiss data on the con-
siderable morbidity and mortality associated with PSC are
also in accordance with ﬁndings from Tischendorf et al.
[28], who described a German cohort of 273 PSC patients
over a median follow-up time of 76 months (which com-
pares well with the follow-up time in the SIBDCS). The
authors found that the estimated median survival from the
time of diagnosis to death or time of liver transplantation
was 9.6 years. In the German cohort, 108 (39.6%) patients
underwent liver transplantation and hepatobiliary malig-
nancies were found in 39 (14.3%) patients.
Our study does have strengths as well as some limita-
tions. The data stem from the large and well-characterized
SIBDCS. We conﬁrm the data of previous cohort studies
reporting on PSC prevalence in UC and CD, associated
risk factors, as well as the signiﬁcantly increased mortality
of IBD patients affected by PSC. A detailed hand search of
source documents (patient ﬁles) was performed in IBD
patients with concomitant PSC to seek information on
items that are not routinely captured by the SIBDCS
questionnaires. One important limitation is that our
national cohort is not population based. As such, IBD
patients recruited in hospitals (80%) are over-represented
compared with those recruited from private practice
(20%). The results may therefore not be applicable to all
IBD patients. Second, we cannot provide incidence data on
PSC in the IBD population. Third, the evaluated risk fac-
tors for CD-PSC patients are not solid enough for
PSC in the SIBDCS Fraga et al. www.eurojgh.com 95
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interpretation, given the small sample size (n= 9 CD-PSC
patients). Fourth, the observed disease duration of UC-PSC
patients (median 13 years) was signiﬁcantly longer com-
pared with the disease duration of UC alone patients
(median 9 years, P=0.005), which increases the risk for
undergoing complications.
In summary, we could conﬁrm previously published
data on PSC prevalence, associated risk factors, and the
unfavorable long-term evolution in a large and well-
characterized cohort of IBD patients. Our data emphasize
the need to pay particular attention during the follow-up
of IBD patients with concomitant PSC.
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